FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Chronic inflammation and HPV16 have been implicated in the disease risk. Most common presentation is urethral bleeding, urethral mass, lower urinary tract symptoms and almost 40% females present with T3/4 disease. Formal examination include EAU, cystoscopy and imaging including CT chest, abdomen and pelvis with increasing use of MRI as well. Location defines prognosis with proximal having worse prognosis. Local regional control is paramount for survival outcomes. While endoscopic resection is feasible it is often inadequate and more extensive resection (penectomy, urethrectomy and/or urinary diversion) may be needed. Lymphadenectomy ipsilateral vs bilateral may be performed if lymph nodes are involved. Radiotherapy may be performed in patients who refuse surgery with results inferior to surgical resection.
World Urological Oncology Federation Symposium at the SIU Congress 2016 - October 20 - 23, 2016 – Buenos Aires, Argentina
Written By: Stephen B. Williams, M.D., Assistant Professor in Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.